Toll-free Number1800 123 1132



The Living Drug for Leukemia

Denvax CAR-T Cell Therapy

A type of cancer Immunotherapy

A revolutionary treatment for Leukemias and Lymphomas

Targeted Treatment

Has the potential to prevent Relapse in Cancer

Personalised Medicine

What is Denvax CAR-T Cell Therapy?

  • CAR-T Cell therapy is a type of treatment in which a patient's T cells (a type of immune cell) are modified in the laboratory so they will attack cancer cells.

    CAR T Cell therapy, a form of cancer immunotherapy, is the current most-exciting field among researchers and oncologists. CAR T-cell therapy is very different and unique and has been shown to eradicate very advanced leukaemia and lymphomas and can keep cancer at bay for many years.

What is Denvax Dendritic Cell Immunotherapy
  • As their name implies, T cells—which help orchestrate the immune response and directly kill cells are the backbone of CAR T-cell therapy.

    Currently available CAR T-cell therapies are customised for each individual patient. They are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognise and bind to specific proteins, or antigens, on the surface of cancer cells, and enable the cancer-killing process.

How it works?

  • For decades, the foundations of cancer treatment have been surgery, chemotherapy, and radiation therapy. These continue to be critical mainstays of treatment, but the discovery of Immunotherapy have recently helped transform the paradigm of cancer treatment.

  • Chimeric Antigen Receptor (CAR) T cells that have been engineered to target CD19 have shown great promise in patients with relapsed and refractory B cell acute lymphocytic leukemia with remission rates of 70-90%.

  • Some remissions have successfully enabled patients to a curable allogeneic stem cell transplant, whereas some responses have been durable without further treatment, and some patients have achieved durable remissions for relapsed ALL (acute lymphocytic leukemia) after an allogeneic stem cell transplant.

What is Denvax Dendritic Cell Immunotherapy
  • Cytokine release syndrome, correlating with the in vivo activation and expansion of T cells, and neurologic toxicity are the most significant side effects and require better understanding and management, and further clinical studies.

  • The decision to include CARTs requires an individualised approach taking into consideration the patient, the disease and therapy-related factors.

  • The CAR-T cells may help guard against recurrence. CAR T cells may eradicate all of the cancer cells and may remain in the body months after the infusion has been completed. The therapy has resulted in long-term remissions for some types of blood cancer

  • Chimeric antigen receptor T-cell clinical trials have generated impressive results in the early outcomes of CAR-T cell therapy patients with blood cancers.

  • In some studies, up to 90 percent of children and adults with B-ALL whose disease had either relapsed multiple times, or failed to respond to standard therapies, achieved remission after receiving CAR T-cell therapy. Relapses may be due to the tumor cells losing the expression of the cluster of differentiation (CD-19) antigen, the limited persistence of CAR T cells, or inhibition of CAR-T cell activity.

  • Studies of CAR-T cell therapy in other blood cancers, including chronic lymphocytic leukemia (CLL), as well as multiple myeloma, also show potential. Research is also under way, exploring the application of CAR T-cell therapy in the treatment of solid tumors.

CAR-T Cell Therapy : The Denvax Process

What is Denvax Dendritic Cell Immunotherapy

The Denvax CAR-T Cell Protocol

  • Chimeric Antigen Receptor CAR-T cell therapy involves modification of a patient's autologous T-cells to express a CAR specific for a tumour antigen, followed by ex vivo cell expansion and re-infusion back to the patient.

    20 ml of blood is collected from the patient, in a CellnuteTM bottle (Transport Medium). T Cells (a type of immune cell) from the patient is drawn, processed and transformed into CAR T cells in the lab in 20 days. These cells are then sent to the Delhi Vasant Vihar medical centre, where the patient is administered the dose under medical supervision with close monitoring of the patient. A thorough workup is done prior to the administration of the therapy.

What is Denvax Dendritic Cell Immunotherapy

Possible Side Effects of CAR-T Cell Therapy